KYRIAD Study
STUDY BASICS
Have you been diagnosed with Functional Hypothalamic Amenorrhea (FHA)? The KYRIAD clinical research study is exploring an investigational treatment as a potential treatment for women with FHA. Participation may last up to 11 months with about 18 study visits. Compensation is provided.
STUDY PURPOSE
If you were diagnosed with functional hypothalamic amenorrhea (FHA), please know that you are not alone in your medical journey. FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the ovaries, which then are not able to cycle and ovulate properly.
Currently, we are working on developing a potential treatment for FHA. KYRIAD is a phase 2 clinical research study that aims to see how well the study treatment helps the body restore the menstrual cycle and to assess its safety. This clinical study is exploring a potential treatment that may support recovery of the menstrual cycle, ovulation and improvement of bone health.
Please note that this clinical trial will use an investigational drug product, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities and which has not received marketing authorization in any country.
COULD THIS STUDY BE RIGHT FOR YOU?
• Are female and between 18 and 40 years of age
• Have been diagnosed with Functional Hypothalamic Amenorrhea (FHA)
• Have had no menstrual bleeding episodes in the last 3 months or longer
WHAT PARTICIPANTS CAN EXPECT
If you join the study, there are certain things you will be expected to do. This includes attending study visits and undergoing certain assessments and procedures, including blood collection, bone scans and gynecological ultrasounds. Your participation may last up to 11 months with about 18 study visits.
IRB: 1409940
- : A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF MIBAVADEMAB IN ADULT WOMEN WITH FUNCTIONAL HYPOTHALAMIC AMENORRHEAMEET THE RESEARCHER
Pouneh Fazeli
Pouneh K. Fazeli, MD, MPH, is an Associate Professor of Medicine in the Division of Endocrinology and Metabolism at the University of Pittsburgh. A graduate of Harvard University, Dr. Fazeli’s research interests include understanding both the benefits and negative consequences of undernutrition.
https://pittplusme.org/study/kyriad